ROBINS HARLAN S 4
4 · Adaptive Biotechnologies Corp · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Adaptive Biotechnologies (ADPT) CSO Harlan Robins Sells Shares
What Happened
Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies (ADPT), sold a total of 42,788 shares in two open-market transactions on Feb 2–3, 2026, for aggregate proceeds of about $799,105. The larger block was 34,668 shares reported at a weighted average price of $18.60 (proceeds $644,825) and the second was 8,120 shares at a weighted average price of $19.00 (proceeds $154,280). These were sales (not purchases), which are often routine disposition of holdings.
Key Details
- Transaction dates and reported prices:
- 2026-02-02: 34,668 shares sold, weighted avg $18.60 (prices ranged $18.26–$18.88) — $644,825 proceeds (F2).
- 2026-02-03: 8,120 shares sold, weighted avg $19.00 (prices ranged $18.56–$19.38) — $154,280 proceeds (F3).
- Total: 42,788 shares sold for approximately $799,105.
- Reported under transaction code S (Sale).
- These sales were executed pursuant to a Rule 10b5-1 trading plan adopted Aug 11, 2025 (F1).
- The filing (Form 4) was dated Feb 4, 2026 for trades on Feb 2–3, 2026 — appears to be timely (Form 4 is generally due within two business days).
- Shares owned after the transaction: not disclosed in the provided filing.
Context
A 10b5-1 plan indicates the trades were pre-planned and may be routine, so they do not necessarily reflect the insider’s current view of the company. For retail investors, purchases typically carry more informational weight than routine sales; this filing documents a scheduled sale under an established plan. The footnotes note weighted-average pricing and offer to provide per-trade price breakouts on request.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-02$18.60/sh−34,668$644,825→ 1,187,644 total - Sale
Common Stock
[F1][F3]2026-02-03$19.00/sh−8,120$154,280→ 1,179,524 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
- [F2]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.26 to $18.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.56 to $19.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.